OXiGENE is a San Francisco-based biopharmaceutical company focused on cancer treatment therapies. The company’s products are designed to destroy the abnormal blood vessels that act as a lifeline to developing cancerous tumors. Several of its therapies have reached Phase II clinical trials for the treatment of ovarian, thyroid, and other forms of cancer. For more information, please visit the company’s website at www.oxigene.com.